Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database
JMIR Public Health and Surveillance · 2023
DOI: 10.2196/45263 ↗At a glance
Journal article in JMIR Public Health and Surveillance, 2023. Written by Hung Thai-Van and 10 co-authors. Institution: Service d'Audiologie & d'Explorations Otoneurologiques, Hospices civils de Lyon, Lyon, France. Major MEDLINE topics: COVID-19, COVID-19 Vaccines, Hearing Loss, Sensorineural, Hearing Loss, Sudden. Cited 9 times so far (Crossref); 70 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
The World Health Organization recently described sudden sensorineural hearing loss (SSNHL) as a possible adverse effect of COVID-19 vaccines. Recent discordant pharmacoepidemiologic studies invite robust clinical investigations of SSNHL after COVID-19 messenger RNA (mRNA) vaccines. This postmarketing surveillance study, overseen by French public health authorities, is the first to clinically document postvaccination SSNHL and examine the role of potential risk factors.
Objective
This nationwide study aimed to assess the relationship between SSNHL and exposure to mRNA COVID-19 vaccines and estimate the reporting rate (Rr) of SSNHL after mRNA vaccination per 1 million doses (primary outcome).
Methods
We performed a retrospective review of all suspected cases of SSNHL after mRNA COVID-19 vaccination spontaneously reported in France between January 2021 and February 2022 based on a comprehensive medical evaluation, including the evaluation of patient medical history, side and range of hearing loss, and hearing recovery outcomes after a minimum period of 3 months. The quantification of hearing loss and assessment of hearing recovery outcomes were performed according to a grading system modified from the Siegel criteria. A cutoff of 21 days was used for the delay onset of SSNHL. The primary outcome was estimated using the total number of doses of each vaccine administered during the study period in France as the denominator.
Results
From 400 extracted cases for tozinameran and elasomeran, 345 (86.3%) spontaneous reports were selected. After reviewing complementary data, 49.6% (171/345) of documented cases of SSNHL were identified. Of these, 83% (142/171) of SSNHL cases occurred after tozinameran vaccination: Rr=1.45/1,000,000 injections; no difference for the rank of injections; complete recovery in 22.5% (32/142) of cases; median delay onset before day 21=4 days (median age 51, IQR 13-83 years); and no effects of sex. A total of 16.9% (29/171) of SSNHL cases occurred after elasomeran vaccination: Rr=1.67/1,000,000 injections; rank effect in favor of the first injection (P=.03); complete recovery in 24% (7/29) of cases; median delay onset before day 21=8 days (median age 47, IQR 33-81 years); and no effects of sex. Autoimmune, cardiovascular, or audiovestibular risk factors were present in approximately 29.8% (51/171) of the cases. SSNHL was more often unilateral than bilateral for both mRNA vaccines (P
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Service d'Audiologie & d'Explorations Otoneurologiques, Hospices civils de Lyon, Lyon, France.
- Département d'audiologie et d'Explorations otoneurologiques, Hôpital Universitaire de lyon 1, Villeurbanne, France.
- Institut de l'Audition, Institut Pasteur, Paris, France.
- Regional Pharmacovigilance Center of Franche-Comté, Centre Hospitalier Universitaire de Besançon, Besançon, France.
- Regional Pharmacovigilance Center of Strasbourg, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France.
- Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance du Centre Val de Loire, Centre Hospitalier Universitaire, Tours. France, Tours, France.
ORCID profiles: Hung Thai-Van, Marie-Blanche Valnet-Rabier, Maëva Anciaux, Aude Lambert, Anaïs Maurier, Judith Cottin, Tessa Pietri, Alexandre Destère, Marlène Damin-Pernik, Fanny Perrouin, Haleh Bagheri
Cite
APA
Thai-Van, H., Valnet-Rabier, M. B., Anciaux, M., Lambert, A., Maurier, A., Cottin, J., Pietri, T., Destère, A., Damin-Pernik, M., Perrouin, F., & Bagheri, H. (2023). Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database. JMIR Public Health and Surveillance. https://doi.org/10.2196/45263
Vancouver
Thai-Van H, Valnet-Rabier MB, Anciaux M, Lambert A, Maurier A, Cottin J, et al. Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database. JMIR Public Health and Surveillance. 2023. doi:10.2196/45263
BibTeX
@article{ThaiVan2023,
author = {Thai-Van, Hung and Valnet-Rabier, Marie-Blanche and Anciaux, Maëva and Lambert, Aude and Maurier, Anaïs and Cottin, Judith and Pietri, Tessa and Destère, Alexandre and Damin-Pernik, Marlène and Perrouin, Fanny and Bagheri, Haleh},
title = {Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database},
journal = {JMIR Public Health and Surveillance},
year = {2023},
doi = {10.2196/45263}
}
EUVIMED